Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Declines By 43.4%

Posted by Stephan Jacobs on Mar 28th, 2025

BioRestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 405,200 shares, a drop of 43.4% from the February 28th total of 715,900 shares. Based on an average daily volume of 371,800 shares, the short-interest ratio is currently 1.1 days. Currently, 8.1% of the shares of the company are short sold.

Hedge Funds Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new position in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX – Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned 0.31% of BioRestorative Therapies at the end of the most recent quarter. 69.38% of the stock is currently owned by institutional investors and hedge funds.

BioRestorative Therapies Stock Performance

NASDAQ BRTX opened at $1.83 on Friday. The firm’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.72. BioRestorative Therapies has a one year low of $1.03 and a one year high of $2.55. The firm has a market cap of $12.66 million, a PE ratio of -1.20 and a beta of 64.37.

About BioRestorative Therapies

(Get Free Report)

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.